JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shu, Y.
Right arrow Articles by Zhou, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shu, Y.
Right arrow Articles by Zhou, H.-H.

Vol. 295, Issue 2, 844-851, November 2000

5-Hydroxylation of Omeprazole by Human Liver Microsomal Fractions from Chinese Populations Related to CYP2C19 Gene Dose and Individual Ethnicity1

Yan Shu2 , Lian-Sheng Wang, Zhen-Hua Xu3 , Nan He, Wei-Min Xiao, Wei Wang, Song-Lin Huang and Hong-Hao Zhou

Pharmacogenetics Research Institute (Y.S., L.-S.W., Z.-H.X., N.H., W.W., S.-L.H., H.-H.Z.) and Department of Pathophysiology (W.-M.X.), Hunan Medical University, Changsha, China

It has been previously reported that omeprazole (OP) oxidation is mediated by CYP2C19 and CYP3A4 in human livers. In this study, we assessed their relative contributions with human liver microsomal fractions from Chinese populations that were genotyped by CYP2C19 and recruited from two ethnic groups, Han and Zhuang. The kinetics of 5-hydroxyomeprazole (5-OH-OP) formation was best described by the two-enzyme and single-enzyme Michaelis-Menten equations for liver microsomes from CYP2C19 extensive (EMs) and poor metabolizers, respectively. At a low substrate concentration that may be encountered in vivo, the monoclonal antibody to CYP2C8/9/19 strongly inhibited 5-OH-OP formation in EM microsomes, whereas troleandomycin (TAO) eliminated most of the formation at a high substrate concentration. In poor metabolizer microsomes, either TAO or anti-CYP3A4 could alone abolish 5-OH-OP formation. Furthermore, there were differences between homozygous and heterozygous EMs in the percentage of inhibition by TAO and the antibodies. At the low substrate concentration, OP 5-hydroxyaltion was correlated well with S-mephenytoin 4'-hydroxylation and CYP2C19 contents in liver microsomes of 34 Chinese individuals. Moreover, in these individuals, obviously genetic and somewhat ethnic differences in OP 5-hydroxylation were observed between different CYP2C19 genotypes (wt/wt > wt/m1 > m1/m1) and between Han and Zhuang (Han > Zhuang), respectively. The results indicate that CYP2C19 is a high-affinity enzyme for OP 5-hydroxylation by liver microsomes from Chinese individuals and that its contribution is CYP2C19 gene dependent and ethnically related. Similar studies indicate that OP sulfoxidation is mediated mainly by CYP3A4 and independent of CYP2C19 genotype status.


1 This work was supported by National Natural Science Foundation of China, No. F39330230, and by China Medical Board of America, No. 92-568 and 99-697.

2 Current address: Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143. E-mail: yans{at}itsa.ucsf.edu

3 Current address: Department of Pharmacology, Mayo Medical School, Rochester, MN 55905. E-mail: Xu.ZhenHua{at}mayo.edu


0022-3565/00/2952-0844$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Z.-Q. Liu, B. Zhu, Y.-F. Tan, Z.-R. Tan, L.-S. Wang, S.-L. Huang, Y. Shu, and H.-H. Zhou
O-Dealkylation of Fluoxetine in Relation to CYP2C19 Gene Dose and Involvement of CYP3A4 in Human Liver Microsomes
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 105 - 111.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.